Neither Baseline nor Changes in Serum Triiodothyronine during Levothyroxine/Liothyronine Combination Therapy Predict a Positive Response to This Treatment Modality in Hypothyroid Patients with Persistent Symptoms
- 19 January 2017
- journal article
- Published by Bioscientifica in European Thyroid Journal
- Vol. 6 (2) , 89-93
Abstract
Background: Despite biochemical euthyroidism, some levothyroxine (L-T4)-treated hypothyroid patients report persisting symptoms and some of these patients are tentatively treated with a combination of L-T4 and liothyronine (L-T3). Combination therapy and the appropriate choice of blood tests to monitor treatment are highly debated among specialists and patients. Aim: To evaluate whether measuring serum triiodothyronine (S-T3) at baseline or during combination therapy can be used as an indicator of a positive effect from L-T4/L-T3 combination therapy. Materials and Methods: Observational retrospective study of patients (n = 42) with persisting symptoms of hypothyroidism despite L-T4 therapy who had normal TSH levels and did not have any comorbidities that could explain their symptoms. All were then treated with L-T4/L-T3 combination therapy at a dose ratio of 17/1 according to European Thyroid Association guidelines. Based on patient-reported outcome, they were divided into responders and nonresponders. Results: Five patients were lost to follow-up and thus excluded. At the 3-month follow-up, 11 were classified as nonresponders and 26 as responders. At 12 months these figures had changed to 13 (35%) and 24 (65%), respectively. When comparing responders versus nonresponders, no differences were seen at baseline or during follow-up in S-T3 and in free T3 estimates. Further, logistic regression showed no correlation between S-T3 and free T3 estimates and responder/nonresponder status. Conclusion: Our data indicate that serum T3 measurements are not suitable to predict which patient will benefit from L-T4/L-T3 combination therapy, and treatment response cannot be followed by repeated T3 measurements either.Keywords
This publication has 18 references indexed in Scilit:
- New insights into the variable effectiveness of levothyroxine monotherapy for hypothyroidismThe Lancet Diabetes & Endocrinology, 2015
- Treating Hypothyroidism with Thyroxine/Triiodothyronine Combination Therapy in Denmark: Following Guidelines or Following Trends?European Thyroid Journal, 2015
- Peripheral markers of thyroid function: the effect of T4 monotherapy vs T4/T3 combination therapy in hypothyroid subjects in a randomized crossover studyEndocrine Connections, 2013
- Polymorphisms in the brain‐specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patientsClinical Endocrinology, 2008
- Triiodothyronine Levels in Athyreotic Individuals During Levothyroxine TherapyJAMA, 2008
- Thyroxine-Triiodothyronine Combination TherapyVersusThyroxine Monotherapy for Clinical Hypothyroidism: Meta-Analysis of Randomized Controlled TrialsThe Journal of Clinical Endocrinology & Metabolism, 2006
- Isotope dilution tandem mass spectrometric method for T4/T3Clinica Chimica Acta, 2004
- HypothyroidismThe Lancet, 2004
- Polymorphisms in Thyroid Hormone Pathway Genes Are Associated with Plasma TSH and Iodothyronine Levels in Healthy SubjectsThe Journal of Clinical Endocrinology & Metabolism, 2003
- Concentrations of Thyroxine and 3,5,3′-Triiodothyronine at 34 Different Sites in Euthyroid Rats as Determined by an Isotopic Equilibrium TechniqueEndocrinology, 1985